Genentech: Jim Kiefer | Senior Scientist and Associate Director, Structural Biology

A link to this page has been copied to your clipboard.

http://www.gene.com/scientists/our-scientists/jim-kiefer

Paste this link in an email to share.

Ok

Scientists / Our Scientists

"Cancer and autoimmune diseases are prevalent among my family and friends. I am here, because I would like to fight back."

Years at Genentech

Publications

My path to Genentech began in the Midwest, working at Searle, Pharmacia, and Pfizer for 12 years, in structure based drug design. Looking from the outside in, I had always been struck by how Genentech was consistently leading, rather than following, in the discovery of new medicines. I have been even more impressed by the culture and innovation here since joining in 2012.

I am structural biologist, but I think of myself as a “molecular photographer.” We determine the shapes of proteins bound to chemicals on the path to potentially becoming drugs and try to improve that interaction. The technique has broad applications from traditional, “small molecule” drugs to protein therapeutics. My primary interests involve pathways triggering cancer and inflammation.

SUMMARY OF PUBLICATIONS (PDF)

Featured Publication

A minor structural change to tertiary sulfonamide RORc ligands led to agonist and inverse agonist mechanisms of action.

ACS Med Chem Lett 6(3):276-281, 2015.

René O, Fauber BP, de Leon Boenig G, Burton B, Eidenschenk C, Everett C, Gobbi A, Hymowitz SG, Johnson AR, Kiefer JR, Liimatta M, Lockey P, Norman M, Ouyang W, Wallweber HA, Wong H.

View Abstract

My role at Genentech has encompassed three different facets. I have been the project leader for a target in the small molecule inflammation portfolio; I provide structures and analysis of them to teams, and I manage one arm of the Structural Biology Department. One of the aspects that I enjoy most about my position at Genentech is the diversity of experiences in my work each week.

I have primarily worked in areas relating to cancer and immunology and was part of the Joint Project Team in Genentech’s and Constellation Pharmaceuticals’ collaboration on Epigenetics research. I have a long-term interest in DNA replication and repair and gene regulation.

Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300

Journal of Medicinal Chemistry, ISSN: 15204804

Terry Crawford; Anthony Romero; Kwong Wah Lai; Vickie Tsui; Alexander M. Taylor; Gladys Boenig; Cameron Noland; Jeremy Murray; Justin Ly; Edna Choo; Thomas Hunsaker; Emily W. Chan; Mark Merchant; Samir Kharbanda; Karen Gascoigne; Sue Kaufman; Maureen Beresini; Jiangpeng Liao; Wenfeng Liu; Kevin Chen; Zhongguo Chen; Andrew R. Conery; Alexandre Côté; Hariharan Jayaram; Ying Jiang; James Kiefer; Tracy Kleinheinz; Yingjie Li; Jonathan Maher; Eneida Pardo; Florence Poy; Kerry L. Spillane; Fei Wang; Jian Wang; Xiaocang Wei; Zhaowu Xu; Zhongya Xu; Ivana Yen; Laura E. Zawadzke; Xiaoyu Zhu; Steve Bellon; Richard T Cummings; Andrea Cochran; Brian K Albrecht; Steven Magnuson

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

A link to this page has been copied to your clipboard.

Jim Kiefer

Senior Scientist and Associate Director, Structural Biology

Featured Publication

A minor structural change to tertiary sulfonamide RORc ligands led to agonist and inverse agonist mechanisms of action.